振东制药：公司创新药乳杆菌二联活菌胶囊Pre-NDA申请已获CDE受理，后续尚需完成提交新药上市申请

Group 1 - The core point of the article is that the company, Zhendong Pharmaceutical, has received acceptance for its Pre-NDA application for the innovative drug Lactobacillus dual live bacteria capsule from the CDE, indicating progress towards potential market entry [2][3] - The company stated that further steps include submitting a new drug marketing application and undergoing rigorous review and on-site inspection processes before the product can be marketed [2] - The company will fulfill its information disclosure obligations based on subsequent developments and advises investors to make cautious decisions and be aware of investment risks [2]